Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

Cheap OEM Software
  

Search in our Online Store
Inflammation
Filter     Order     Display # 
Date Item Title
17 Nov 2008 Start of the Phase II clinical trial with Elafin
13 Nov 2008 Actelion's first-in-class selective S1P1 receptor agonist to enter Phase II clinical development
13 Nov 2008 BioSeek Licenses Two Novel Anti-Inflammatory Peptides
13 Nov 2008 Antibody Shows Ability to Inhibit Disease in an Established RA Model
13 Nov 2008 BioLineRx and Yissum Sign a Licensing Agreement for the Development of a Novel Compound for the Treatment of Inflammatory Bowel Disease
12 Nov 2008 Transdermal Diclofenac enters Phase 1 Clinical Trial in Humans
11 Nov 2008 Rigel's R788 Phase 2a Results Published in Arthritis and Rheumatism
10 Nov 2008 Celgene Cellular Therapeutics Receives FDA Clearance for First Placenta-Derived Stem Cell Clinical Study
10 Nov 2008 Results of Studies of ALVESCO(R) for the Treatment of Asthma and OMNARIS(TM) in an HFA Nasal Aerosol Presented at American College of Allergy, Asthma & Immunology Annual Meeting
10 Nov 2008 Gene Signal Enters Phase III Clinical Tests for the Prevention of Corneal Graft Rejection
06 Nov 2008 SCOLR Pharma, Inc. Announces Positive Top-Line Results From Pivotal Clinical Trial Evaluating Efficacy of Extended-Release Ibuprofen
06 Nov 2008 Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients
03 Nov 2008 Antiangiogenic Role of 2ME2 Demonstrated in Rheumatoid Arthritis Models
30 Oct 2008 New Cimzia(R) study shows rapid reduction of symptoms and progression of rheumatoid arthritis
30 Oct 2008 Welichem Reports Positive Phase IIa Clinical Results
29 Oct 2008 Revotar reports positive preclinical data from a 4-month dermal toxicity study
29 Oct 2008 Phase 2a Data for MEDI-528 Presented at CHEST 2008
29 Oct 2008 Launch of a ph.III clinical trial in adults for Oralair Grasses in the US
28 Oct 2008 Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus
28 Oct 2008 Seattle Genetics Presents on SGN-70 at American College of Rheumatology Meeting
28 Oct 2008 Active Biotech Presents New Data regarding the 57-57 SLE Project at American College of Rheumatology Meeting
28 Oct 2008 Nuvo Research Presents Positive Phase III Study Results For Pennsaid At Leading Rheumatology Conference
28 Oct 2008 Nanocort(R) demonstrates safety and good response in Phase I/II trial
27 Oct 2008 Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
27 Oct 2008 CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
27 Oct 2008 Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis
27 Oct 2008 WEHI Spin-Out MuriGen Restructures G-CSF Antagonist Program With CSL
27 Oct 2008 New data shows ACTEMRA inhibits progression of joint destruction and improves physical function of patients with Rheumatoid Arthritis
27 Oct 2008 ACZ885 Phase III data show rapid, sustained clinical remission in children and adults suffering from a group of rare, potentially life-threatening autoinflammatory diseases
27 Oct 2008 CombinatoRx Provides In-Depth Analysis from Phase 2b Knee Osteoarthritis Study of Synavive (CRx-102) with Clinical Investigators
27 Oct 2008 Incyte's JAK Inhibitor Demonstrates Rapid and Marked Clinical Improvement in Rheumatoid Arthritis Patients
27 Oct 2008 New Study Shows ENBREL(R) (etanercept) Is More Effective than a DMARD in the Treatment of Symptoms of Ankylosing Spondylitis Patients
27 Oct 2008 One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
26 Oct 2008 FDA has accepted for filing the first potential once-a-day nasal antihistamine
25 Oct 2008 Lexicon Presents Phase 1 Clinical Trial Results for LX2931 at American College of Rheumatology Annual Meeting
25 Oct 2008 New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients
23 Oct 2008 MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
23 Oct 2008 XOMA Presents Data On XOMA 052, An Anti-IL-1 Beta Antibody, in Rheumatoid Arthritis and Acute Gout Animal Models
21 Oct 2008 Abbott’s HUMIRA(R) (adalimumab) Data Shows Fistula Healing for Up to Three Years in Patients with Moderate to Severe Crohn’s Disease
21 Oct 2008 Clinical Update – Debio 9902 SR (ZT-1) for Alzheimer Patients - Debiopharm Starts Tablet Formulation Bridging Study under IND
17 Oct 2008 MediGene: RhuDex(TM)to be Examined in Further Laboratory Tests
15 Oct 2008 ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 Into Clinical Development
13 Oct 2008 Revotar reports positive Phase I data in psoriasis with its Bimosiamose 5% Cream
10 Oct 2008 AVONTEC announces the results of a successful proof of concept within a phase 2a study with its drug candidate AVT-02 UE ointment after topical treatment in patients with mild-to-moderate psoriasis
10 Oct 2008 Phase II-b trials for Oglemilast(GRC 3886) in Asthma initiated
09 Oct 2008 Evotec Announces Phase I Initiation with P2X7 Antagonist
09 Oct 2008 SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
09 Oct 2008 Icagen Initiates Phase II Proof-of-Concept Trial in Allergic Asthma for Senicapoc Potassium Channel Blocker
09 Oct 2008 Biogen Idec Announces Top-Line Results from Phase II Clinical Trial of Baminercept in Rheumatoid Arthritis
07 Oct 2008 In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 1 - 50 of 927

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Diabetes Drug Pipeline

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics